These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 18343246

  • 1. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
    Barrios V, Escobar C, Tomás JP, Calderon A, Echarri R.
    Clin Ther; 2008 Jan; 30(1):98-107. PubMed ID: 18343246
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
    Baguet JP, Asmar R, Valensi P, Nisse-Durgeat S, Mallion JM.
    Vasc Health Risk Manag; 2009 Jan; 5(1):175-83. PubMed ID: 19436670
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.
    Nielsen FS, Rossing P, Gall MA, Smidt UM, Chen JW, Sato A, Parving HH.
    Scand J Clin Lab Invest; 1997 Aug; 57(5):427-34. PubMed ID: 9279969
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.
    Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, Schwandt P, Ludwig M, MORE study investigators.
    Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):97-106. PubMed ID: 19124398
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R, Kahan T, Malmqvist K, Ring M, Edner M.
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [Abstract] [Full Text] [Related]

  • 17. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group.
    Os I, Stokke HP.
    J Cardiovasc Pharmacol; 1999 May; 33(5):791-7. PubMed ID: 10226868
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.